[go: up one dir, main page]

DK1673104T4 - Fremføring af terapeutiske forbindelser til hjernen og andre væv - Google Patents

Fremføring af terapeutiske forbindelser til hjernen og andre væv Download PDF

Info

Publication number
DK1673104T4
DK1673104T4 DK04782579.9T DK04782579T DK1673104T4 DK 1673104 T4 DK1673104 T4 DK 1673104T4 DK 04782579 T DK04782579 T DK 04782579T DK 1673104 T4 DK1673104 T4 DK 1673104T4
Authority
DK
Denmark
Prior art keywords
promotion
brain
tissues
therapeutic
connections
Prior art date
Application number
DK04782579.9T
Other languages
English (en)
Other versions
DK1673104T3 (da
Inventor
Emil D Kakkis
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34217412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1673104(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of DK1673104T3 publication Critical patent/DK1673104T3/da
Application granted granted Critical
Publication of DK1673104T4 publication Critical patent/DK1673104T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04782579.9T 2003-08-29 2004-08-30 Fremføring af terapeutiske forbindelser til hjernen og andre væv DK1673104T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/651,493 US7442372B2 (en) 2003-08-29 2003-08-29 Delivery of therapeutic compounds to the brain and other tissues
PCT/US2004/028135 WO2005021064A2 (en) 2003-08-29 2004-08-30 Delivery of therapeutic compounds to the brain and other tissues

Publications (2)

Publication Number Publication Date
DK1673104T3 DK1673104T3 (da) 2014-01-20
DK1673104T4 true DK1673104T4 (da) 2022-01-17

Family

ID=34217412

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04782579.9T DK1673104T4 (da) 2003-08-29 2004-08-30 Fremføring af terapeutiske forbindelser til hjernen og andre væv

Country Status (12)

Country Link
US (5) US7442372B2 (da)
EP (1) EP1673104B2 (da)
JP (1) JP5819574B2 (da)
AU (1) AU2004268645B2 (da)
CA (1) CA2537238C (da)
CY (1) CY1114815T1 (da)
DK (1) DK1673104T4 (da)
ES (1) ES2441612T5 (da)
PL (1) PL1673104T5 (da)
PT (1) PT1673104E (da)
SI (1) SI1673104T2 (da)
WO (1) WO2005021064A2 (da)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6585971B1 (en) * 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
JP2008503590A (ja) * 2004-06-21 2008-02-07 メドトロニック・インコーポレーテッド 組成物を細胞にデリバリーするための医学用システム及び方法
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
PT1988823T (pt) 2006-02-09 2018-11-22 Genzyme Corp Administração intraventricular lenta
EP2046435A4 (en) * 2006-07-13 2012-06-27 Medtronic Inc METHOD AND FORMULATIONS FOR OPTIMAL LOCAL ADMINISTRATION OF CELL THERAPY BY MEANS OF MINIMALLY INVASIVE PROCEDURES
US8849372B2 (en) * 2006-11-22 2014-09-30 The General Hospital Corporation Method for magnetic resonance imaging using stimulus induced rotary saturation with a contrast agent
WO2008070769A1 (en) * 2006-12-06 2008-06-12 Medtronic, Inc. Intrathecal catheter
WO2008089339A2 (en) * 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting
ES2417146T3 (es) * 2007-01-18 2013-08-06 Genzyme Corporation Oligosacáridos que comprenden un grupo aminoxi y conjugados de los mismos
ES2635726T3 (es) * 2007-06-06 2017-10-04 Genzyme Corporation Terapia génica para enfermedades de almacenamiento lisosómico
US8366652B2 (en) 2007-08-17 2013-02-05 The Invention Science Fund I, Llc Systems, devices, and methods including infection-fighting and monitoring shunts
US8460229B2 (en) 2007-08-17 2013-06-11 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having components that are actively controllable between transmissive and reflective states
US8162924B2 (en) 2007-08-17 2012-04-24 The Invention Science Fund I, Llc System, devices, and methods including actively-controllable superoxide water generating systems
US8734718B2 (en) 2007-08-17 2014-05-27 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component
US8114346B2 (en) * 2007-08-17 2012-02-14 The Invention Science Fund I, Llc Event-triggered ultraviolet light sterilization of surfaces
US8029740B2 (en) 2008-07-11 2011-10-04 The Invention Science Fund I, Llc Event-triggered self-sterilization of article surfaces
US20090048648A1 (en) * 2007-08-17 2009-02-19 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Self-sterilizing device
US9005263B2 (en) 2007-08-17 2015-04-14 The Invention Science Fund I, Llc System, devices, and methods including actively-controllable sterilizing excitation delivery implants
US8706211B2 (en) 2007-08-17 2014-04-22 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having self-cleaning surfaces
US8647292B2 (en) 2007-08-17 2014-02-11 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having components that are actively controllable between two or more wettability states
US8753304B2 (en) 2007-08-17 2014-06-17 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having acoustically actuatable waveguide components for delivering a sterilizing stimulus to a region proximate a surface of the catheter
US8702640B2 (en) 2007-08-17 2014-04-22 The Invention Science Fund I, Llc System, devices, and methods including catheters configured to monitor and inhibit biofilm formation
CA2696699A1 (en) * 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
US20100266569A1 (en) * 2007-11-15 2010-10-21 Mark Zylka Prostatic acid phosphatase for the treatment of pain
US20110223147A1 (en) 2008-05-07 2011-09-15 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US20120041287A1 (en) 2008-12-04 2012-02-16 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including implantable devices with anti-microbial properties
US8585627B2 (en) 2008-12-04 2013-11-19 The Invention Science Fund I, Llc Systems, devices, and methods including catheters configured to monitor biofilm formation having biofilm spectral information configured as a data structure
HUE044381T2 (hu) 2008-12-16 2019-10-28 Genzyme Corp Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállításához
EP3679942A1 (en) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
EP3998078B1 (en) * 2009-08-28 2025-10-01 Icahn School of Medicine at Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
SMT201900594T1 (it) * 2010-06-25 2019-11-13 Shire Human Genetic Therapies Metodi e composizioni per il rilascio nell’snc di iduronato-2-solfatasi
UA129740C2 (uk) 2010-06-25 2025-07-23 Такеда Фармасьютікал Компані Лімітед Застосування композиції, що включає білок арилсульфатази а (аса)
EP2588132A4 (en) * 2010-06-25 2014-10-15 Shire Human Genetic Therapies METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS
JP6063380B2 (ja) * 2010-06-25 2017-01-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド サンフィリポ症候群ｂ型の処置
WO2011163648A1 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
CN103282046B (zh) * 2010-06-25 2015-05-13 夏尔人类遗传性治疗公司 芳基硫酸酯酶 a cns 递送的方法和组合物
US9320711B2 (en) * 2010-06-25 2016-04-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan N-sulfatase
JP2012062312A (ja) * 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
RS60129B1 (sr) 2011-01-20 2020-05-29 Protalix Ltd Kompozicije alfa-galaktozidaze
RU2014117291A (ru) * 2011-10-12 2015-11-20 Синаджева Биофарма Корп. Рекомбинантный человеческий белок naglu и его применение
US9101678B2 (en) 2011-11-03 2015-08-11 Elwha Llc Heat-sanitization of surfaces
WO2013070760A1 (en) * 2011-11-07 2013-05-16 Shire Human Genetic Therapies, Inc. Biomarkers for sanfilippo syndrome and uses thereof
CA2857647C (en) * 2011-12-02 2022-04-19 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
WO2013096912A2 (en) * 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
WO2014022515A1 (en) * 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
WO2014022841A1 (en) * 2012-08-03 2014-02-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Cyclodextrin for the treatment of lysosomal storage diseases
DK3115372T3 (da) 2012-11-27 2019-06-11 Biomarin Pharm Inc Målrettede terapeutiske lysosomale enzymfusionsproteiner og anvendelser deraf
EA201590582A1 (ru) * 2012-12-07 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для лечения мукополисахаридоза типа iiia с использованием интратекального введения
WO2014130723A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
EP3622821A1 (en) * 2013-05-15 2020-03-18 Regents of the University of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
US9994641B2 (en) 2013-12-25 2018-06-12 Jcr Pharmaceuticals Co., Ltd. Anti-human transferrin receptor antibody that passes through blood-brain barrier
TWI752907B (zh) 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
BR112017026287A2 (pt) 2015-06-10 2018-09-18 Vtesse Inc composições de hidroxipropil beta-ciclodextrina e métodos
US11130815B2 (en) 2015-06-24 2021-09-28 Jcr Pharmaceuticals Co., Ltd. Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody
CN107849555B (zh) 2015-06-24 2022-01-04 Jcr制药股份有限公司 通过血脑屏障的抗人转铁蛋白受体抗体
JP2018538008A (ja) 2015-11-06 2018-12-27 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム酵素の取り込みを中和する抗体または他の因子の検出のための細胞ベースアッセイ
BR112018017322A2 (pt) 2016-02-24 2019-01-02 Biomarin Pharm Inc proteínas de fusão de enzima lisossômica terapêuticas direcionadas, formulações associadas e usos das mesmas
MA44874A (fr) 2016-04-15 2019-03-13 Univ Pennsylvania Thérapie génique pour traiter la mucopolysaccharidose de type ii
EP4248971A3 (en) * 2016-06-02 2024-02-14 ADS Therapeutics LLC Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
AU2017284198B2 (en) 2016-06-13 2023-09-28 The University Of North Carolina At Chapel Hill Optimized CLN1 genes and expression cassettes and their use
CN110100000B (zh) 2016-12-26 2023-06-20 Jcr制药股份有限公司 含有bdnf的融合蛋白
WO2018124121A1 (ja) 2016-12-26 2018-07-05 Ｊｃｒファーマ株式会社 血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体
US11723865B2 (en) 2017-02-08 2023-08-15 New Hope Research Foundation, Inc. Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord
US11541005B2 (en) 2017-02-08 2023-01-03 New Hope Research Foundation, Inc. Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord
IL273427B2 (en) 2017-09-22 2025-04-01 Univ Pennsylvania Gene therapy for the treatment of mucocutaneous polycythemia vera type II
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
US11730767B2 (en) 2018-02-23 2023-08-22 Regeneration Biomedical, Inc. Methods, apparatuses and systems for instilling stem cells and pharmaceuticals into the human ventricular system
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EA202190416A1 (ru) 2018-08-02 2021-06-23 Дайн Терапьютикс, Инк. Мышечно-специфические комлексы и их применение для лечения плече-лопаточно-лицевой мышечной дистрофии
DK3688147T3 (da) * 2018-12-18 2022-12-19 Neuway Pharma Gmbh Hidtil ukendt lægemiddelindgivelsessystem og fremgangsmåder til tilvejebringelse heraf
EP3670652A1 (en) * 2018-12-18 2020-06-24 NEUWAY Pharma GmbH Vlp for the treatment of a lysosomal storage disease
WO2020132100A1 (en) 2018-12-19 2020-06-25 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules for lysosomal targeting and related compositions and methods
US11446084B2 (en) 2019-07-12 2022-09-20 Neuralink Corp. Laser drilling of pia mater
HRP20240871T1 (hr) 2019-08-29 2024-10-11 Biomarin Pharmaceutical Inc. Postupci liječenja cln2 bolesti kod pedijatrijskih subjekata
CA3164707A1 (en) 2020-02-03 2021-08-12 Ana Maria Garcia Collazo Combination therapy for treating mps1
KR102880902B1 (ko) * 2021-01-29 2025-11-03 현대자동차주식회사 셀 기반 모빌리티 생산시스템의 운영방법
EP4291237A4 (en) * 2021-02-09 2025-01-15 Phoenix Nest Inc. Nootropic peptides for treating lysosomal storage diseases
WO2023288033A1 (en) 2021-07-14 2023-01-19 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
CA3244449A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Hydroxypropyl-beta-cyclodextrin compositions and related purification methods
WO2025125542A1 (en) * 2023-12-15 2025-06-19 F. Hoffmann-La Roche Ag Intrathecal dosage method

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2601215A (en) 1948-03-17 1952-06-17 American Cyanamid Co Process of preparing dihydropterins
US3505329A (en) 1968-02-06 1970-04-07 Smithkline Corp Process for the synthesis of biopterin
JPS5883691A (ja) 1981-11-13 1983-05-19 Kanegafuchi Chem Ind Co Ltd １′，２′−ジアシル−（６ｒ，ｓ）−５，６，７，８−テトラヒドロ−ｌ−ビオプテリンおよびその製法
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
CH651755A5 (en) 1982-03-03 1985-10-15 Kanegafuchi Chemical Ind Use of pterin derivatives
JPS5976086A (ja) 1982-09-20 1984-04-28 ザ　ウエルカム　フアウンデ−シヨン　リミテツド プテリジン化合物
GB8318833D0 (en) 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
US5196533A (en) 1983-04-11 1993-03-23 South Alabama Medical Science Foundation, Usa Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines
US4587340A (en) 1983-09-19 1986-05-06 Burroughs Wellcome Co. Biopterin analogs
JPS60178887A (ja) 1984-02-23 1985-09-12 Kanegafuchi Chem Ind Co Ltd ５，６，７，８−テトラヒドロ−ｌ−ビオプテリンの製造法
JPS60199889A (ja) 1984-03-24 1985-10-09 Kanegafuchi Chem Ind Co Ltd ５，６，７，８−テトラヒドロ−ｌ−エリスロ−ビオプテリンの硫酸塩およびその製法
US4550109A (en) 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
DE3437944A1 (de) 1984-10-17 1986-07-31 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verwendung von pterinen zur steigerung der aktivitaet von lymphokinen und anderen blutfaktoren, sowie ein diagnostisches oder therapeutisches praeparat, das pterine in kombination mit lymphokinen enthaelt
US4713454A (en) 1985-01-28 1987-12-15 Shiratori Pharmaceutical Co., Ltd. Preparation process of (6R)-tetrahydro-L-biopterin
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1334654C (en) 1987-11-30 1995-03-07 Masayasu Kurono Intermediates for synthesizing bh _and its derivatives
US6149909A (en) 1995-06-23 2000-11-21 Women's And Children's Hospital Synthetic α-L-iduronidase and genetic sequences encoding same
JP2534423B2 (ja) 1991-12-26 1996-09-18 コーネル・リサーチ・ファンデーション・インコーポレイテッド 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤
US5198547A (en) 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
US5981194A (en) 1992-07-10 1999-11-09 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
DE4308739C1 (de) 1993-03-19 1994-06-23 Henning Berlin Gmbh Pterinderivate, ihre Herstellung und ihre Verwendung
US5945452A (en) 1993-06-11 1999-08-31 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5502050A (en) 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
ES2177654T3 (es) 1994-08-05 2002-12-16 Suntory Ltd Remedio contra la degeneracion espinocerebelosa.
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5929304A (en) 1995-09-14 1999-07-27 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
CA2205710A1 (en) 1996-05-20 1997-11-20 The University Of British Columbia Murine model for generalized lysosomal storage disorder and methods of making and using same
US20020076782A1 (en) 1996-07-05 2002-06-20 John P.N. Rosazza Purified nitric oxide synthase
GB9617990D0 (en) 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
US6458574B1 (en) † 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US5922713A (en) 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
JP4306825B2 (ja) 1998-02-27 2009-08-05 アスビオファーマ株式会社 インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤
BR9910323A (pt) * 1998-05-13 2001-01-30 Harbor Ucla Alfa-l-iduronidase recombinante, métodos para produção e purificação da mesma e métodos para tratamento de doenças ocasionadas deficiência da mesma
US6200758B1 (en) 1999-02-19 2001-03-13 New York State Office Of Mental Health Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
CA2367002A1 (en) 1999-03-19 2000-09-28 Michael A. Moskowitz Increasing cerebral bioavailability of drugs
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
EP1227828A1 (en) * 1999-11-12 2002-08-07 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
US6569661B1 (en) 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6426208B1 (en) 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6585971B1 (en) 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
AU1775901A (en) * 1999-11-17 2001-05-30 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
US6972124B2 (en) * 2000-05-01 2005-12-06 Biomarin Pharmaceuticals Inc. Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
US20020006400A1 (en) 2000-05-11 2002-01-17 Peter Lobel Recombinant human CLN2 protein and methods of its production and use
US6544994B2 (en) 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
DK2767291T3 (da) 2000-07-18 2016-12-05 Univ Duke Behandling af glycogenlagringssygdom type II
US20050119270A1 (en) 2000-08-04 2005-06-02 Mason R. P. Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release
EP1314782B1 (en) 2000-08-31 2009-03-18 Asubio Pharma Co., Ltd. Process for producing biopterins
DE60224816T2 (de) * 2001-04-30 2009-01-22 ZyStor Therapeutics, Inc., Milwaukee Subzelluläres targeting von therapeutischen proteinen
WO2002098455A2 (en) † 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
US20030007961A1 (en) 2001-06-22 2003-01-09 Wilburn Michael D. Orthomolecular vitamin E derivatives
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003086452A2 (en) 2002-04-05 2003-10-23 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
US20030198620A1 (en) 2002-04-16 2003-10-23 Keiya Ozawa Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions
EP1503788B1 (en) 2002-04-25 2011-06-29 Shire Human Genetic Therapies, Inc. Treatment of alpha-galactosidase a deficiency
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
DE10260263A1 (de) 2002-12-20 2004-07-15 Biocrates Life Sciences Gmbh Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen
US7855063B2 (en) 2003-04-16 2010-12-21 Yeda Research And Development Co. Ltd. Partially deglycosylated glucocerebrosidase polypeptide and crystals thereof
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1638605B1 (en) * 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
MX2007005039A (es) 2004-11-17 2007-06-19 Biomarin Pharm Inc Formulacion de tableta estable.

Also Published As

Publication number Publication date
US20170182134A1 (en) 2017-06-29
JP5819574B2 (ja) 2015-11-24
CA2537238A1 (en) 2005-03-10
US11040088B2 (en) 2021-06-22
PT1673104E (pt) 2014-01-15
US20150150799A1 (en) 2015-06-04
US9572870B2 (en) 2017-02-21
US20090017005A1 (en) 2009-01-15
WO2005021064A2 (en) 2005-03-10
WO2005021064A3 (en) 2005-08-25
US20120148558A1 (en) 2012-06-14
JP2007504166A (ja) 2007-03-01
SI1673104T2 (sl) 2022-01-31
CY1114815T1 (el) 2016-12-14
EP1673104B2 (en) 2021-10-27
CA2537238C (en) 2015-01-06
SI1673104T1 (sl) 2014-02-28
US9089566B2 (en) 2015-07-28
PL1673104T3 (pl) 2014-03-31
DK1673104T3 (da) 2014-01-20
AU2004268645B2 (en) 2010-02-18
US20050048047A1 (en) 2005-03-03
US7442372B2 (en) 2008-10-28
AU2004268645A1 (en) 2005-03-10
PL1673104T5 (pl) 2023-03-06
ES2441612T5 (es) 2022-04-04
EP1673104B1 (en) 2013-10-09
EP1673104A4 (en) 2009-08-12
EP1673104A2 (en) 2006-06-28
ES2441612T3 (es) 2014-02-05
US9044473B2 (en) 2015-06-02

Similar Documents

Publication Publication Date Title
DK1673104T4 (da) Fremføring af terapeutiske forbindelser til hjernen og andre væv
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
IS8913A (is) Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk
DK1678194T3 (da) Modulering af syntese og degradering af hyaluronan i behandlingen af sygdom
IS7977A (is) Samsetningar og aðferð til samsettra meðferðar
DK1917246T3 (da) Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
DK1485127T3 (da) Anvendelse af midler til behandling af inflammation
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
MA28802B1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
DK1835924T3 (da) Behandling af parkinsons sygdom og beslægtede sygdomme under anvendelse af postpartum opnåede celler
IS8371A (is) Notkun breyttra sýklósporína til að meðhöndla HCVsjúkdóma
EP1622633A4 (en) Treatment of t-cell mediated diseases
NO20055246D0 (no) Heteroaromatisk pentasyklisk forbindelse og medisinsk anvendelse derav
IS8142A (is) Læknislyf gagnleg til meðferðar á verkjum
IS8530A (is) Meðferð á truflunum í auga þar með talinni sjóndepilsrýrnun
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DK1537096T3 (da) Derivater af dioxan-2-alkylcarbamater, fremstilling og terapeutisk anvendelse heraf
IS7523A (is) Framleiðsla á súlfínýl asetamíði
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
DK1599469T3 (da) Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed
DK1670482T4 (da) Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme